3 British Biotech Stocks With P E Under 27 To Watch

The Bank of England has lifted interest rates for the first time in years, pushing up borrowing costs just as living expenses bite harder. Higher rates often squeeze highly indebted firms, which puts financially healthier British biotech stocks in sharper focus. This article highlights three UK biotechnology companies from our quality-focused screen that combine reasonable balance sheets and valuations, helping you concentrate on potential winners rather than speculative long shots.

The three stocks that follow are just a sample from our quality screen, and the full filter surfaced 4 more British biotech companies with equally compelling stories that are not covered below. To go beyond this short list and really sort through the sector, head straight into the Biotech Stocks screener to identify, compare, and analyze the highest conviction biotech ideas for your watchlist.

AstraZeneca is one of the few large biopharma groups in this screen that gives you genuine biotech exposure through a huge oncology and biologics engine, while still being anchored by a broad prescription medicines portfolio across cancer, respiratory, cardiometabolic and rare diseases.

AstraZeneca develops, manufactures, and sells prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases, with all of its US$62.4b revenue coming from pharmaceuticals and a market value of about £216.1b.

“The company’s robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management’s disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range. The missed primary endpoint in the Ultomiris trial for HSCT associated thrombotic microangiopathy underlines the possibility that some complement and rare disease extensions do not translate into registrational data strong enough for broad use.”

The real swing factor for AstraZeneca is how one concentrated piece of this future portfolio ultimately feeds through into margins and long term cash generation.

That margin question is exactly what the full narrative for AstraZeneca unpacks, setting out how AstraZeneca’s pipeline, capital allocation, and risk trade offs could reshape the long term story.

Hikma Pharmaceuticals gives you biotech exposure through its oncology and complex injectables work, but wraps that inside a much broader generic and branded drugs portfolio that earns US$1.4b from Injectables, US$1.0b from Hikma Rx, US$914 million from Branded and carries a market value near £3.4b.

For investors hunting for biotech upside without going all in on early stage science, Hikma Pharmaceuticals offers a middle ground, where oncology linked assets sit inside a wider, cash generative platform that is now being reshaped by a clear shift in how research money is spent.

“Hikma Pharmaceuticals is materially increasing R&D investment and concentrating it through three global platforms with disciplined NPV and IRR stage gates, which aims to shift the portfolio toward fewer, higher value complex products that can support higher net margins and earnings quality over time.”

The real test is how one pressure on future pricing for those complex therapies plays out against what investors expect from margins.

That pricing squeeze is exactly what the full narrative for Hikma Pharmaceuticals unpacks, showing where Hikma Pharmaceuticals could still accelerate returns if complex injectables outpace generic margin pressure.

Genus plugs into the biotech theme through its animal genetics work, using genomic tools to improve dairy and pork herds while still operating as a diversified agriculture supplier.

Genus generates about £355.8 million from Genus PIC and £299.8 million from Genus ABS, with only £2.5 million from central operations, and carries a market value around £1.5b.

Genus gives you biotech exposure through animal genetics that is tied to real world demand for dairy and pork. This can appeal if you want science backed products but prefer a business grounded in selling breeding stock, semen, embryos, and related services rather than early stage drug trials.

“The build out of Genus’ high margin, recurring PIC royalty model, including more than 50% royalty revenue growth in China on top of 6% group royalty growth in H1 FY26, points to further expansion of royalty driven revenue and operating profit as contracts mature and penetrate a larger share of global pig herds.”

What really shapes the long term picture is how one shift in earnings quality and cash conversion affects the value investors place on those royalties.

As that earnings mix keeps shifting, the full narrative for Genus maps how royalty momentum, capital intensity, and herd cycle risks could be decoupling Genus’ long term potential from short term noise.

Seeking Alternatives Beyond Biotech?

Fresh ideas move first. By the time every investor spots a breakout or dropping laggard, the best entry can be gone. Scan these curated lists before the crowd and act now.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com